To the Editor:
We read with great interest the article published in The Journal by Luque Ramos, et al1, in which the comorbidities of rheumatoid arthritis (RA) are detailed, explaining specifically the thromboembolic processes. The authors mentioned that the risk was double in patients with RA compared to controls. We present 2 cases in which the diagnosis of pulmonary thromboembolism was made in patients whose only known risk factor was RA.
It has been widely studied and shown that patients with systemic inflammatory diseases such as RA have a higher risk of mortality from cardiovascular diseases than the healthy population. However, it is postulated that chronic inflammation favors a procoagulant state, which leads to a higher incidence of thromboembolic diseases. This hypothesis has been shown retrospectively, assessing the incidence of both deep venous thrombosis and pulmonary embolism in cohorts affected by RA and comparing them with those of the general population.
The first case is a 45-year-old patient with seropositive RA diagnosed in 2012 and treated with methotrexate at a dose of 17.5 mg and prednisone at a dose of 20 mg a day, without other medical history of interest. The second case is an 86-year-old patient without toxic habits and allergic to vitamin B12, diagnosed with seropositive RA with positive anticyclic citrullinated peptide in 2004 and in usual treatment with prednisolone 20 mg/day, having never received treatment with disease-modifying antirheumatic drugs (DMARD). Both patients were diagnosed with pulmonary thromboembolism, initiating treatment with anticoagulants with a correct subsequent course. In the 2 cases, both the study of hidden neoplasia and the alteration in coagulation factors were negative, ruling out other causes of pulmonary thromboembolism.
RA means a continuous proinflammatory state, although this can be controlled with DMARD. Inflammation of autoimmune diseases modulates thrombotic responses by procoagulant hyperstimulation, decreased anticoagulant processes, and suppression of fibrinolysis.
Patients with RA have a considerably shorter life expectancy than the healthy population, mainly owing to an increase in the incidence of cardiovascular events2,3. To date, most studies focus on explaining the relationship between the proinflammatory state and arteriosclerotic alterations and their complications. However, there are few studies of the relationship between the systemic entity and thromboembolic disease [either deep vein thrombosis (DVT) or pulmonary thromboembolism]. In 2012, Zöller, et al showed that hospitalized patients with RA had a higher risk of DVT than the rest of the hospitalized population, especially after the first year when the risk of pulmonary thromboembolism was up to 6 times higher, and then decreased over the next 5 years postdiagnosis4. The problem with these studies is that they were performed on a population with an RA exacerbation (the main reason for hospital admission), without assessing thromboembolic risk in the population with nonhospitalized RA (which is the predominant population)5,6. In 2014, Choi, et al conducted a study to evaluate the increased risk of DVT and pulmonary thromboembolism in the nonhospitalized population2. They demonstrated that patients with RA had a risk ratio (RR) of 2.23 (95% CI 1.75–2.86) of having pulmonary thromboembolism, compared to the general population, adjusting these results by sex, age, and time of diagnosis of the disease. When adjusting the results for body mass index, smoking, hospitalizations, and other comorbidities (such as chronic obstructive pulmonary disease), the RR remained 2.16 (95% CI 1.68–2.79) for the pulmonary embolism and 2.16 (95% CI 1.74–2.69) for venous thromboembolism. The cause of the increased risk in this population, although not thoroughly studied, may be that proinflammatory states are a key factor for the correct function of the endothelium in both arterial and venous circulation7.
Patients with RA maintain a chronic proinflammatory state that determines a dysfunction in the vascular endothelium (arterial and venous), thus increasing the risk of thromboembolic events.
Footnotes
All patients described signed written informed consent to publish the material.
